RESUMEN
Objective o evaluate the efficacy and safety of perampanel in the treatment of refractory partial-onset seizures.Methods The randomized controlled trials ofperampanel in treatment of refractory partial-onset seizures were searched from PubMed,EBSCO,EMbase,Cochrane Library,CBM,CNKI,VIP database,and Wanfang database by computer.Data were collected from establishment of the database to February 2017 and the each index was analyzed by meta-analysis with RevMan 5.0 software.Results Five RCT were included,including 1 500 patients with refractory partial-onset seizures.Meta-analysis results showed that there was a significant difference between perampanel and placebo in term of seizure-free rate [OR=3.75,95％CI(1.77,7.93),P =0.000 6] and percentage of patients achieving 50％ reduction in seizure frequency [OR=2.08,95％CI(1.69,2.56),P ＜ 0.001].Common adverse reactions of perampanel were dizziness,somnolence,headache,ataxia,nasopharyngifis,etc.The total rate of adverse reactions of the two Perampanel groups of 8 mg group and 12 mg group doses were higher than placebo group (P ＜ 0.05).Conclusion The clinical efficacy of perampanel in the treatment of refractory partial-onset seizures,and the adverse reactions is slight,patient is well tolerated.
RESUMEN
Objective o evaluate the efficacy and safety of perampanel in the treatment of refractory partial-onset seizures.Methods The randomized controlled trials ofperampanel in treatment of refractory partial-onset seizures were searched from PubMed,EBSCO,EMbase,Cochrane Library,CBM,CNKI,VIP database,and Wanfang database by computer.Data were collected from establishment of the database to February 2017 and the each index was analyzed by meta-analysis with RevMan 5.0 software.Results Five RCT were included,including 1 500 patients with refractory partial-onset seizures.Meta-analysis results showed that there was a significant difference between perampanel and placebo in term of seizure-free rate [OR=3.75,95％CI(1.77,7.93),P =0.000 6] and percentage of patients achieving 50％ reduction in seizure frequency [OR=2.08,95％CI(1.69,2.56),P ＜ 0.001].Common adverse reactions of perampanel were dizziness,somnolence,headache,ataxia,nasopharyngifis,etc.The total rate of adverse reactions of the two Perampanel groups of 8 mg group and 12 mg group doses were higher than placebo group (P ＜ 0.05).Conclusion The clinical efficacy of perampanel in the treatment of refractory partial-onset seizures,and the adverse reactions is slight,patient is well tolerated.
RESUMEN
Background: Anti N-methyl-D-aspartate (NMDA) receptor encephalitis is an immune mediated disorder. Case characteristics: A previously healthy 14-year-old girl presenting with generalized tonic clonic seizures and altered behavior. Observation: In view of refractory seizures, hallucinations, psychobehavioral and catalepsy like symptoms, and CSF showing lymphocytic pleocytosis, possibility of autoimmune encephalitis was considered. Serum was positive for anti-NMDA receptor antibodies. Outcome: She recovered completely in six months without any sequelae. Conclusion: Anti-NMDA receptor encephalitis - a potentially treatable disease - should be considered in differential diagnosis of encephalitis when acute behavioral changes, seizures or dyskinesias are present.
RESUMEN
Tuberous Sclerosis Complex (TSC) is a neurocutaneous disorder characterised by hamartoma formation in multiple organs, particularly the skin, brain, eye, kidney and heart. It is rare for TSC to manifest as intractable seizures without cutaneous manifestations. Targeted history elicitation along with appropriate systemic examination backed by proper investigations in high index of suspicion is mandatory to diagnose a case of TSC in such scenario. We report such a case where a 27 year old male was diagnosed with TSC following admission with refractory seizures.
RESUMEN
El Estado Epiléptico (EE) es una emergencia médica, que requiere intervención de forma inmediata para disminuir la morbimortalidad asociada. Esta incluye el uso de medidas de soporte vital, y un tratamiento específico cuyo objetivo es detener todas las crisis ya sean clínicas o electrográficas y prevenir su recurrencia. En el presente manuscrito revisamos lo más relevante del tratamiento farmacológico en cada estadío del EE y las medidas generales concomitantes, para un manejo adecuado.
Status Epilepticus is a medical emergency requiring immediate intervention to decrease morbidity and mortality. This includes the use of life support measures and specific treatment aimed at stopping all crises either clinical or electrographic and prevents its recurrence. In this manuscript we review the most relevant of drug treatment at each stage of the Status Epilepticus and the concomitant general measures for proper management.